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Hantavirus infections cause severe emerging diseases in humans and are associated 
with high mortality rates; therefore, they have become a global public health concern. 
Our previous study showed that the CD8+ T-cell epitope aa129–aa137 (FVVPILLKA, 
FA9) of the Hantaan virus (HTNV) nucleoprotein (NP), restricted by human leukocyte 
antigen (HLA)-A*02, induced specific CD8+ T-cell responses that controlled HTNV infec-
tion in humans. However, the in vivo immunogenicity of peptide FA9 and the effect of 
FA9-specific CD8+ T-cell immunity remain unclear. Here, based on a detailed structural 
analysis of the peptide FA9/HLA-A*0201 complex and functional investigations using 
HLA-A2.1/Kb transgenic (Tg) mice, we found that the overall structure of the peptide 
FA9/HLA-A*0201 complex displayed a typical MHC class I fold with Val2 and Ala9 as 
primary anchor residues and Val3 and Leu7 as secondary anchor residues that allow 
peptide FA9 to bind tightly with an HLA-A*0201 molecule. Residues in the middle por-
tion of peptide FA9 extruding out of the binding groove may be the sites that allow for 
recognition by T-cell receptors. Immunization with peptide FA9 in HLA-A2.1/Kb Tg mice 
induced FA9-specific cytotoxic T-cell responses characterized by the induction of high 
expression levels of interferon-γ, tumor necrosis factor-α, granzyme B, and CD107a. 
In an HTNV challenge trial, significant reductions in the levels of both the antigens 
and the HTNV RNA loads were observed in the liver, spleen, and kidneys of Tg mice 
pre- vaccinated with peptide FA9. Thus, our findings highlight the ability of HTNV epi-
tope-specific CD8+ T-cell immunity to control HTNV and support the possibility that the 
HTNV-NP FA9 peptide, naturally processed in vivo in an HLA-A*02-restriction manner, 
may be a good candidate for the development HTNV peptide vaccines.
Keywords: hantaan virus, hla-a*02, cytotoxic T-cell epitope, crystal structure, cD8+ T-cell response, hla-a2.1/
Kb transgenic mice
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inTrODUcTiOn
As widespread emerging zoonotic pathogens, hantaviruses, 
which belong to the Bunyaviridae family, have significant and 
growing impacts on global public health (1). Murine-borne 
hantavirus transmissions cause more than 200,000 cases annu-
ally of human disease worldwide and a significant portion of 
the world’s population is at risk of being infected (2). Some 
hantaviruses, such as the Hantaan virus (HTNV) in Asia, the 
Dobrava virus and Puumala virus (PUUV) in Europe, and the 
Seoul virus worldwide, can lead to hemorrhagic fever with renal 
syndrome (HFRS) in humans, and other hantaviruses, such as 
the Sin Nombre virus (SNV) and the Andes virus (ANDV) in 
North and South America directly cause human hantavirus 
pulmonary syndrome (HPS) (3–5). Infection by any of the sero-
types can lead to a broad spectrum of outcomes, ranging from 
asymptomatic infection to acute fever and hemorrhage, and 
even life-threatening shock and acute kidney or lung injury (6). 
In China, a total of 1,625,002 HFRS cases and 46,968 deaths were 
reported during the years of 1950–2014 with a case-fatality rate 
as high as 15% (6). Over 90% of the total global HFRS cases that 
arose in China were caused by infection with the HTNV strain, 
the prototype member of the hantavirus family (7–9). In the 
U.S., based on the Centers for Disease Control and Prevention 
report, the total HPS cases from the years of 1993–2015 reached 
659, with a higher case-fatality rate of ~36%, thereby raising the 
concern of the World Health Organization. This situation is fur-
ther exacerbated by the periodic emergence of novel species of 
hantaviruses, leading to a disruption of the healthcare systems in 
epidemic areas and a major health concern worldwide (10–12). 
Although some live attenuated or inactive vaccines have been 
used in some parts of the world and have partially prevented 
hantaviruses infections, there remains an urgent need for more 
effective therapeutic or prophylactic vaccines to better control 
the epidemic situation (13, 14).
The negative-sense RNA genome encoding two structure 
proteins, nucleocapsid protein (NP) and envelope glycoprotein, 
give rise to the primary antigenicity of HTNV. The HTNV-NP 
has been demonstrated as highly immunogenic and conserva-
tive, responsible for vigorous cellular and humoral immune 
responses (15), and the heterodimers of mature HTNV glyco-
proteins, Gn and Gc, are considered the main sources of neutral-
izing antibody production in humans (16). It has been suggested 
that the immunological mechanisms for viral clearance are 
related closely with T-cell-mediated immune responses. This 
notion is supported by evidence that hantavirus-specific T cells 
play a critical role in the control of virus infection (17–19). 
Our previous results have demonstrated that the T-cell response 
during the acute stage of HFRS in patients is characterized by 
vigorous cytotoxic T cell (CTL) responses and multifunctional 
T helper (Th) cell responses against HTNV infection (20, 21). 
Patients with milder severities of HFRS typically mount vigor-
ous HTNV-specific CD4+ and CD8+ T-cell responses directed 
against the epitopes of HTNV, whereas patients with severe or 
critical HFRS tend to have weak and narrowly focused T-cell 
responses (20–22). Moreover, we also reported that CD8+ 
T cells specific to the immunodominant epitope of HTNV-NP, 
the aa129–aa137 epitope (FVVPILLKA, FA9), was restricted 
by human leukocyte antigen (HLA)-A*02 and displayed poly-
functional activity, including cytotoxic activity, the ability to 
proliferate, and the ability to produce the effector cytokines. 
The finding of the negative correlation between HTNV-NP 
FA9 epitope-primed CD8+ T-cell responses and disease severity 
suggests at least partial control of HTNV infection in HFRS 
patients (21).
Although the genome of the virus could potentially encode a 
multitude of T-cell epitopes, the specific T-cell response against 
viral infections often focuses on a few epitopes, which is known 
as immunodominance. The HLA-A*02-restricted HTNV-NP 
epitope FA9 that we previously identified was not only the 
immunodominant epitope but also a highly conserved epitope 
with 67–100% concordance among hantaviruses compared 
to the sequences of with other serotypes (21). To study the 
response induced by HLA-A*02-restricted HTNV-NP epitopes, 
we have previously used peptide–HLA (pHLA)-pentamers to 
detect the frequencies of HTNV-NP epitope-specific CD8+ 
T cells in the peripheral blood mononuclear cells (PBMCs) of 
HLA-A*02-positive HFRS patients (21). Because encounters 
between T-cell receptors (TCRs) and pHLA appear to be a key 
factor for the immunogenic potential of CD8+ T-cell responses, 
structural studies examining the pHLA should be highly rel-
evant in understanding the cellular immune response to HTNV 
infection. X-ray crystal structures could reveal the structure of 
the closed conformation of the peptide/HLA complex (23–26). 
However, very few crystal structures demonstrating the interac-
tion between HTNV epitopes and HLA molecules have been 
analyzed to date.
HLA-A*02 is the most prevalent HLA class I allele among 
the Chinese Han population, which has been considered to be 
associated with the control of many viral infections (27, 28). It is 
well-established that the HLA-A*02-restricted HTNV-NP FA9 
epitope elicits highly effective CD8+ T-cell responses associated 
with reduced serum virus loads in HFRS individuals. However, 
it remains unclear whether the HTNV-NP FA9 epitope can 
induce a strong CD8+ T-cell immunity against HTNV infection 
in vivo. Humanized mice, which are mice engrafted with human 
tissue and/or are engineered to express human genes, are con-
sidered powerful tools for studying species-restricted pathogen 
that can induce in vivo human immunity (29–31). Therefore, a 
“humanized” HLA-A2.1/Kb transgenic (Tg) mouse model that 
expresses a chimeric monochain of HLA-A*02 infected with 
HTNV would be an ideal virus replication model to explore the 
effect of in  vivo responses primed by epitope FA9. The study 
of HTNV-NP FA9 peptide-specific responses in HLA-A2.1/Kb 
Tg mice may provide an opportunity to further understand 
the in vivo mechanism of HTNV-specific CD8+ T cells against 
virus replication.
For immuno-prophylaxis of HTNV infection, inactive 
HTNV vaccines have been provided for free vaccinations 
against HFRS to high-risk populations in China for more than 
a decade. An epidemiological survey revealed the feasibility, 
safety, and immunogenicity of the inactive vaccine. However, 
the efficacy of the vaccine should be improved to further reduce 
the risk of infection (32). The peptides in vivo may mimic the 
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epitopes that are presented and restricted the MHC to target 
cells, thus inducing relevant immune responses. Therefore, 
the development of peptide vaccines may be a better method 
to specifically direct the cellular immune system against 
pathogens. Given to the critical roles of the HTNV-NP FA9 
epitope, which can induce protective CD8+ T-cell responses, 
such epitopes may be appealing targets for peptide vaccine 
development. However, although the HTNV-NP FA9 peptide 
presented by HLA-A*02 has been well characterized in  vitro, 
the pHLA interaction, which may directly correlate to the 
efficacy of peptide vaccines and the effect of the HTNV-NP 
FA9 epitope in mice after challenge with HTNV remain largely 
unclear. Identifying these mechanisms is critical for the design 
of more effective HTNV peptide vaccines.
The collective results in this study illustrate the interaction 
between HTNV-NP peptide FA9 and HLA-A*02 molecules and 
demonstrate that FA9 vaccinations in HLA-A2.1/Kb Tg mice were 
able to control HTNV challenge upon induction of the effective 
cellular immune response to HTNV. The HTNV-NP FA9 peptide 
was identified as an immunogenic epitope that is naturally pro-
cessed in vivo in an HLA-A*02-restricted manner. These findings 
provide crucial information for better evaluating T-cell immunity 
against HTNV infection, which may have important implications 
for the diagnosis and immuno-targeting of HFRS and may help 
guide the development of safe and effective T-cell-based HTNV 
peptide vaccines for humans.
MaTerials anD MeThODs
ethic statement
This study was performed in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory 
Animals of the National Health and Medical Research Council 
of China. The protocol was approved by the Committee on the 
Ethics of Animal Experiments of the Fourth Military Medical 
University with the license number XJYYLL-2014437. All pro-
cedures were performed under sodium pentobarbital anesthesia, 
and every effort was made to minimize animal suffering.
Viruses and Vaccine
The HTNV 76-118 strain was kindly provided by the Department 
of Microbiology of our university. The commercial HFRS 
inactivated vaccine (YOUERJIAN®, Zhejiang Tianyuan Bio- 
Pharmaceutical Co., Ltd., China) derived from a mixture of both 
HTNV and SEOV was provided as a bivalent and purified HFRS 
vaccine.
Peptide synthesis
Based on the epitopes we identified previously (21), the 9-mer 
aa129–aa137 peptide on HTNV-NP (FVVPILLKA, FA9) restric-
ted by HLA-A*02 and the aa131–aa139 peptide on HTNV-NP 
(VPILLKALY, VY9) restricted by HLA-B*35 were synthesized at 
90% purity, as assessed by high-performance liquid chromatog-
raphy and mass spectroscopy (CL Bio-scientific, Xi’an, China). 
Peptides were resuspended in a sterile phosphate-buffered 
saline (PBS) solution at 1 mM and stored in aliquots at −80°C 
before use.
T2 cells Binding assay with synthetic 
Peptides
A lymphoblast cell line, designated as T2 (174 × CEM. T2), was 
purchased from the American Type Culture Collection (cat. no. 
CRL-1992™; Manassas, VA, USA). This cell line is transporter-
associated with antigen processing (TAP)-deficient and expresses 
HLA-A*02. Cells were cultured in RPMI 1640 culture medium 
containing 10% fetal bovine serum (Gibco, Grand Island, NY, 
USA), 100  U/ml penicillin and 100  mg/ml streptomycin. The 
T2 cell-binding assay was performed as described elsewhere 
to determine the binding capability of synthetic peptides to 
HLA-A*0201 molecules (33). Briefly, T2 cells were incubated 
with 50 μmol/l peptide, and 1 μmol/l human β2-microglobulin 
(β2m, Sigma) in serum-free RPMI 1640 medium for 18 h at 37°C 
with 5% CO2. The expression of HLA-A*0201 by the T2 cells was 
then determined by staining with fluorescein isothiocyanate 
(FITC)-labeled anti-HLA-A2 monoclonal antibody (mAb) 
BB7.2 (Biolegend) and detected by flow cytometry (FACScan; 
BD Biosciences). The results are presented as the fluorescent 
index (FI), which was determined as follows: FI =  (mean PE 
fluorescence with the given peptide −  mean PE fluorescence 
without peptide)/(mean PE fluorescence without peptide). FI ≥ 1 
represents high-affinity peptides (34), indicating that the peptide 
stably combined with HLA-A*0201 molecules on the surface of 
T2 cells to increase the mean fluorescence of the HLA-A*0201 
molecules by at least onefold.
Protein expression, refolding, 
and Purification
Refolding of the HTNV-NP-derived FA9 peptide with the 
HLA-A*0201 heavy chain and β2m was performed as described 
previously (33–35). Briefly, the HLA-A*0201 heavy chain (extra-
cellular domain aa1–aa275) and β2m were expressed as inclusion 
bodies in Escherichia coli using the pET prokaryotic expression 
system (Novagen Inc.). Then, the inclusion bodies were sepa-
rately dissolved in a solution of 10 mM Tris/HCl (pH 8.0) and 
8 M urea. The HLA-A*0201 heavy chain, β2m and the peptide 
were subsequently mixed at a molecular ratio of 1:1:3 into a 
refolding buffer (100  mM Tris/HCl, 400  mM l-arginine-HCl, 
2 mM EDTA, 0.5 mM oxidized glutathione, and 5 mM reduced 
glutathione; Sigma). After incubation at 4°C for 24 h, the soluble 
refolded complex was concentrated using a bicinchoninic acid 
(BCA) protein assay (Pierce) and purified by gel filtration, fol-
lowed by anion exchange chromatography using a Superdex 
G-200 (Amersham Pharmacia Biotech) to ensure the correctly 
refolded pHLA complex. Finally, the complex was concentrated 
to 10 mg/ml in 20 mM Tris–HCl (pH 8) and 50 mM NaCl for 
crystallization.
X-ray crystallography, Data collection, 
and structure Determination
Crystal screens were initiated using commercial kits (Hampton 
Research). The crystals were obtained from vapor-diffusion 
hanging drops containing equal volumes of protein [10  mg/
ml; 25  mM 2-(N-morpholino) ethanesulfonic acid (MES), 
pH 6.5] and 16% polyethylene glycol 6000 in 25  mM MES 
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(pH 6.5). Plates were incubated at 291  K and examined after 
72  h and 1  week. The diffractable crystals were soaked in 
a reservoir solution supplemented with 20% glycerol as a 
cryoprotectant, then flash-cooled and maintained at 100 K in 
a cryostream and obtained by subsequent microseeding. The 
data were collected on a Rigaku R-AXIS IV++ image plate 
using a Rigaku MicroMax 007 rotation-anode X-ray in-house 
generator (Rigaku) operating at 40  kV and 20  mA (Cu Kα; 
λ = 1.5418 Å). The data were processed and scaled using the 
HKL2000 (HKL Research Inc.).
hla-a2.1/Kb Transgenic Mice
HLA-A2.1/Kb Tg mice purchased from the Jackson Laboratory 
(BarHarbor, ME, USA) were kindly provided by Dr. Yuzhang 
Wu (Third Military Medical University, Chongqing, China) 
and maintained in the Animal House Facility at the Center for 
Laboratory Animal, Fourth Military Medical University, Xi’an, 
China. The Tg mice created in a C57BL/6 background represent 
a chimeric gene consisting of the α1 and α2 domains of HLA-
A*0201 and the α3 transmembrane and cytoplasmic domain of 
H-2Kb. Cell-surface HLA-A*02 expression was assessed by flow 
cytometry using phycoerythrin (PE)-labeled anti-HLA-A*02 
mAb BB7.2.
immunization of hla-a2.1/Kb  
Tg Mice with the Peptide
The HLA-A2.1/Kb Tg mice were divided into four groups (n = 6 
each). Immunizations of the Tg mice with the peptide were carried 
out using the N-terminal fragment of the murine glycoprotein 96 
(gp96) as an adjuvant (35, 36). Briefly, each 6- to 8-week-old male 
HLA-A2.1/Kb Tg mouse was immunized via subcutaneously 
injection at multiple sites with 50 μg of HLA-A*02-restricted FA9 
peptide, emulsified in complete or incomplete Freund’s adjuvant 
(Difco) and 30 μg of the N-terminal fragment N333 (aa22–aa355) 
of murine gp96. The injection volume was adjusted to 100 μl for 
each animal. Three immunization injections were administered 
to each mouse at intervals of 2  weeks. The same method was 
used for immunization with the HLA-B*35-restricted epitope 
VY9 as the uncorrelated peptide control group. Subcutaneous 
injections with the HFRS inactivated vaccine and PBS were used 
as the positive and negative control groups, respectively. Ten days 
after the last immunization, the splenocytes were isolated and 
erylysed. Specific cytokine-producing cells were detected via an 
Enzyme-Linked Immunospot (ELISPOT) assay and intracellular 
staining.
hTnV challenge
A preliminary experiment was conducted to determine the 
infection of the HTNV 76-118 strain in naive HLA-A2.1/Kb 
Tg mice following HTNV challenge. Ten days after the final 
immunization booster, the mice were challenged with the HTNV 
76-118 strain by intramuscular injection (1 ×  105  pfu/mouse). 
The Tg mice were sacrificed 4 days following HTNV challenge. 
Tissue samples, including the cerebrum, heart, liver, spleen, 
lungs, and kidneys, were weighed and prepared as 10% (gram/
milliliter) tissue suspensions in PBS. Then, the tissue samples 
were freeze-thawed (−80°C/37°C) three times after grinding 
and centrifuged at 12,000 × rpm for 30 min at 4°C to collect the 
supernatants of the tissue.
Ex Vivo iFn-γ enzyme-linked  
immunospot assay
The determination of the immunogenicity of the HTNV-NP 
9-mer peptide in  vivo was performed using an interferon 
(IFN)-γ ELISPOT assay (Mabtech, Büro Deutschland, 
Germany), as previously described (20). Briefly, the splenocytes 
obtained from HLA-A2.1/Kb Tg mice were placed in duplicate 
on ELISPOT plates at 1 × 106 cells/well and stimulated over-
night with peptides (10 μM). Cells with phytohemagglutinin 
(PHA, 10  μg/ml, Sigma-Aldrich, St. Louis, MO, USA) or 
no peptide stimulation served as positive and background 
controls, respectively. Spots formed by the deposition of the 
enzyme substrate were counted using an ELISPOT plate reader 
(Cellular Technology Limited, USA). Adjusted spot-forming 
cells (SFC) after subtracting the average negative values are 
expressed as SFC/106 splenocytes. The positive response was 
defined as at least 50  SFC/106 input cells, exceeding three 
times the background response after subtracting the number of 
spots in the background controls from those in the stimulated 
samples. The SFC/106 splenocytes in the unstimulated control 
wells never exceeded five spots per well.
intracellular cytokine staining 
and cD107a Degranulation assay
Splenocytes (2 × 106) obtained from HLA-A2.1/Kb Tg mice that 
had been immunized were restimulated with peptide (5 μM), 
as previously described (20). Briefly, Brefeldin A (10  μg/ml; 
Sigma-Aldrich, St. Louis, MO) and the costimulatory molecules 
anti-CD49d (clone 9F10) and anti-CD28 (clone CD28.2) (1 μg/
ml, Biolegend) were added to the culture for 6 h at 37°C. The 
CD107a-PE antibody (BD Pharmingen) was added to the 
wells during the stimulation. Cells stimulated with phorbol 
myristate acetate (PMA, 0.1 μg/ml, Sigma-Aldrich, St. Louis, 
MO, USA)-ionomycin (0.05 μg/ml, Sigma-Aldrich, St. Louis, 
MO, USA) or medium alone were used as positive and negative 
controls, respectively. Cells were labeled with anti-mouse CD3 
and anti-mouse CD8α mAbs (BD Biosciences Pharmingen), 
fixed and permeabilized using a BD Cytofix/Cytoperm kit 
(BD Biosciences Pharmingen), and then stained with PE or 
APC-labeled anti-IFN-γ, PE-labeled anti-tumor necrosis fac-
tor (TNF)-α, FITC-labeled anti-granzyme B and PE-labeled 
anti-CD107a mAbs (BD Biosciences Pharmingen). FITC-, PE-, 
PerCP–Cy5.5-, and APC-conjugated mouse IgG1, κ were used 
as isotype controls of the 4-color staining. A total of 200,000 
events per sample were collected using a FACSCalibur flow 
cytometer (BD Biosciences). The analysis was performed 
immediately with FlowJo version 9.2 (TreeStar). Splenocytes 
were defined as FSC/SSC, and CD8+ T cells were defined as 
CD3+CD8+ events, displayed on a dot plot of CD8 versus 
cytokines. The cytokine response was considered positive 
when the percentage of cytokine was greater than 0.1% after 
background subtraction.
FigUre 1 | Binding affinity of the hTnV nucleoprotein Fa9 peptide to hla-a*0201 molecule. (a) MHC stabilization assay with T2 cells was used to quantify 
the peptide-binding affinity of HTNV nucleoprotein (NP) FA9 (aa129–aa137, FVVPILLKA) to HLA-A*0201 molecule via flow cytometry. HLA-B*35-restricted HTNV-NP 
VY9 (aa131–aa139, VPILLKALY) unrelated peptides served as negative controls. The red curve indicates T2 cells incubated without peptide. The blue curve 
indicates T2 cells incubated with peptide VY9. The orange curve indicates T2 cells incubated with peptide FA9. The overlay of the three conditions in histograms 
clearly demonstrate that the curve of T2 cells incubated with peptide FA9 is shifted more to the right than that incubated with peptide VY9 or without peptide. The 
results shown are representative of three independent experiments. (B) In vitro refolding of the HTNV-NP FA9 peptide with the HLA-A*0201 heavy chain and β2m. 
The refolded complex was analyzed by gel filtration chromatography using a Superdex 200 16/60 column. The peak of the HLA complex as indicated by the arrow 
with the expected molecular mass of 45 kDa eluted at the estimated volume of 15.9 ml. mAU, milli-absorbance units.
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Detection of hTnV antigens by  
enzyme-linked immunosorbent assay
Hantaan virus antigens in the supernatants of the major tissues of 
Tg mice were detected by sandwich enzyme-linked immunosorb-
ent assay (ELISA). Anti-HTNV-NP mAb 1A8 was prepared in the 
Department of Microbiology of our university. The mAb 1A8 and 
horseradish peroxidase-conjugated 1A8 were used as the coating 
and detecting antibodies, respectively (37). The normal tissue 
supernatants were used as negative controls. The absorbance was 
measured at a wavelength of 490 nm using a standard ELISA plate 
reader (Bio-red). OD490 values exceeding 2.1-fold of the negative 
controls (P/N) were considered positive results.
Determination of relative hTnV rna 
loads with Quantitative rT-Pcr
The major organs, including the heart, liver, spleen, lungs, kid-
neys, and brain, of post-exposure Tg mice were preserved in a 
non-frozen tissue RNA preservation solution (Solarbio, CN) at 
−4°C. The tissue RNA of each organ was extracted using RNA 
purification extraction kits (Tiangen Biotech, CN) and used as a 
template for reverse transcription using PrimeScript™ RT-PCR 
kit (Takara) to obtain the cDNA. The target sequence of the HTNV 
S segment was detected in the major organs using a SYBR real-
time quantification PCR kit (Takara) with the following primers: 
HTNV forward, 5′-GATCAGTCACAGTCTAGTCA-3′; HTNV 
reverse, 5′-TGATTCTTCCACCATTTTGT-3′; mouse GAPDH 
forward, 5′-AGGCCGGTGCTGAGTATGTC-3′; mouse GAPDH 
reverse, 5′-TGCCTGCTTCACCACCTTCT-3′. The results were 
recorded as cycle time (Ct) and quantified by 2−ΔΔCt.
statistical analysis
Statistical analyses and graphing were performed using SPSS 
16.0 (SPSS Inc., Chicago, IL, USA) and Prism software, version 
5.0 (Graphpad; La Jolla, CA, USA). The frequency of the CD8+ 
T cells and the cytokines secreted are presented as the medians 
and range values. The Wilcoxon rank-sum test was used for 
parameter comparison between the two subject groups. A two-
tailed P-value below 0.05 (p ≤ 0.05) was considered statistically 
significant.
accession numbers
HTNV 76-118 strain nucleoprotein GenBank accession number: 
M14626. The hantaviruses used in this study, corresponding to 
the HTNV 76-118 strain: NC_005218. The structure of the GV9 
(GLMWLSYFV)/HLA-A*0201complex was deposited in the 
Protein Data Bank with the accession number: PDB code 3I6G.
resUlTs
The synthesized hTnV-nP Fa9 Peptide 
exhibited high Binding affinity to the 
hla-a*0201 Molecule
Our previous findings showed that the HTNV-NP FA9 peptide 
restricted by HLA-A*02 induced an effective CD8+ T-cell response 
in HFRS patients (21). To further investigate the binding affinity 
of peptide FA9 to an HLA-A*02 molecule, a T2 cell-peptide-
binding assay was conducted. The synthesized peptide FA9 
increased the surface expression of HLA-A*0201 molecules, cor-
responding to a FI value of 2.77, indicating that peptide FA9 had 
a high affinity for binding with HLA-A*0201 molecules, whereas 
the HLA-B*35-restricted peptide aa131–aa139 (VPILLKALY, 
VY9) on HTNV-NP used as a negative control showed an FI 
of 0.14, indicating no binding with HLA-A*0201 (Figure 1A). 
Moreover, the HLA-A*0201 complex refolding assay showed that 
the predicted molecular weight of the protein coming out with 
~15.9  ml eluting buffer would be 45  kDa, coincident with the 
molecular mass of the pHLA complex (Figure 1B and Figure S1 
in Supplementary Material). Therefore, the results suggest that 
FigUre 2 | The structure of hla-a*0201 complexed with the hTnV nucleoprotein Fa9 peptide. The crystals were obtained from vapor-diffusion hanging 
drops and the data were processed and scaled using the HKL2000. (a) Overview of the three-dimensional structure of the FA9/HLA-A*0201complex showing a 
typical MHC class I fold. The antigenic peptide-binding groove was constituted by antiparallel α1 and α2 helices in the extracellular region of the HLA-A*0201 heavy 
chain, and supported by an eight-stranded β-sheet bedplate. The HTNV nucleoprotein (NP) FA9 (aa129–aa137, FVVPILLKA) peptide was presented in the 
peptide-binding cleft. The α3 domain and β2m occupied the standard positions below the bedplate. (B) Structural superposition of the FA9/HLA-A*0201 complex 
and the previously determined HLA-A*0201 structure complexed with peptide GV9 (GLMWLSYFV, PDB code: 3I6G). The structure of FA9/HLA-A*0201 is similar to 
the structure of GV9/HLA-A*0201 with a low root mean square difference (RMSD) of 0.415 Å. (c) The alignment of peptide FA9 with peptide GV9. The mainchain 
conformation of FA9 is similar to GV9. The residues Val2 and Ala9 (red arrows) act as the primary anchor residues of FA9, which exhibit the same conformations as 
Leu2 and Val9 of GV9. The residues Val3 and Leu7 (green arrows) act as secondary anchor residues for peptide FA9, whereas the residues Met3 and Ser6 might be 
the secondary anchors for the peptide GV9. The residues Phe1, Pro4, Ile5, Leu6, and Lys8 (blue arrows) of peptide FA9 pointing upwards from the HLA-A*0201 
surface are the most probable recognition sites for TCRs. (D) The electron density for peptide FA9 at σ = 1.0 contour level.
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the HTNV-NP FA9 peptide binds with an HLA-A*0201 molecule 
with a high binding affinity.
structural evidence of Peptide 
Presentation of hTnV-nP Fa9  
by the hla-a*0201 Molecule
To further confirm that the HTNV-NP FA9 peptide is a typical 
HLA-A*02-restricted epitope, the crystal structure of peptide FA9 
bound to HLA-A*0201 was further analyzed. Crystal trials were 
carried out with the purified heterodimer of the heavy chain and 
β2-microglobulin (β2m) expressed in E. coli, and the synthesized 
cognate peptide was refolded. The diffracting crystals of pHLA 
were then obtained (Figure S2 in Supplementary Material). As 
expected, the overall three-dimensional structure and domain 
arrangements of the FA9/HLA-A*0201 complex showed a typical 
MHC class I fold, which was exactly similar to those of the for-
merly determined peptide/HLA-A*0201 molecules (Figure 2A). 
Specifically, the antiparallel α1 and α2 helices in the extracellular 
region of the HLA-A*0201 heavy chain formed the antigenic 
peptide-binding groove, which was supported by an eight-
stranded β-sheet bedplate. The α3 domain and β2m occupied the 
standard positions below the bedplate (Figure  2A). Compared 
with the previously determined HLA-A*0201 complexed with 
peptide GV9 (GLMWLSYFV, PDB code: 3I6G), the structural 
superposition of FA9/HLA-A*0201 was similar to that of GV9/
HLA-A*0201 with a low root mean square difference (RMSD) 
of 0.415  Å. The amino acid sequence alignments revealed that 
the main chain conformation of FA9 is quite similar to GV9 
(Figures  2B,C). Specifically, the residues Val2 and Ala9 act as 
primary anchor residues of peptide FA9, which perform the same 
conformation as Leu2 and Val9 of peptide GV9. The residue Val 
at position 2 from the N-terminus and the residue Ala9 at the 
C-terminal of peptide FA9 were deeply buried in the pocket, indi-
cating typical anchor residues (Figure 2C). Of particular interest 
were the residues Val3 and Leu7, which point their side chains 
into the pocket and might act as secondary anchor residues for 
peptide FA9 to bind with HLA-A*0201. However, Met3 and Ser6 
FigUre 3 | The analysis of interferon (iFn)-γ secretion by splenocytes 
of hla-a2.1/Kb transgenic mice against hTnV nucleoprotein peptide 
Fa9. Comparison of the magnitudes (y-axis) of ex vivo ELISPOT IFN-γ 
responses to the HTNV nucleoprotein (NP) FA9 peptide (aa129–aa137, 
FVVPILLKA) among the different groups (x-axis). The HLA-A2.1/Kb transgenic 
mice were divided into four groups (n = 6 each), including the mice 
immunized with the HLA-A*02-restricted HTNV-NP FA9 peptide, the 
HLA-B*35-restricted HTNV-NP VY9 (aa131–aa139, VPILLKALY) as an 
unrelated peptide control, the HTNV vaccine as a positive control and PBS 
as a negative control, respectively. Three immunization injections were 
administered to each mouse at intervals of 2 weeks. Ten days after the last 
immunization, the splenocytes were isolated for IFN-γ detection by ELISPOT 
assay. The magnitudes of the responses are represented as the spot-forming 
cells (SFC)/106 splenocytes. A02-FA9 indicates the HLA-A2.1/Kb transgenic 
mice immunized with the HLA-A*02-restricted HTNV-NP FA9 peptide. 
B35-VY9 indicates the transgenic mice immunized with the HLA-B*35-
restricted HTNV-NP VY9 peptide. The Wilcoxon rank-sum test was used for 
statistical evaluation. ns, not significant.
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might be the secondary anchors for the peptide GV9 (Figure 2C). 
Although there were differences in residues observed between 
the FA9 and GV9 peptides, the crystal structures revealed that 
the two peptides adopted similar conformations in their binding 
with an HLA-A*0201 molecule. All of these anchor residues help 
the peptide tightly bind with the HLA-A*0201 heavy chain and 
enhance the stability of the entire complex. It is also important 
to note that the centrally located residues on the main chain 
of peptide FA9 tended to protrude out of the antigen-binding 
groove. The side chains of Phe1, Pro4, Ile5, Leu6, and Lys8 are the 
most exposed residues pointing upwards from the HLA-A*0201 
surface, indicating that these amino acids are the most probable 
recognition sites for TCRs and might be involved in TCR docking 
(Figure 2C). The mutants in these positions may influence the 
antigenicity of the peptide and even lead to the immune escape 
of the virus. The further unambiguous electron density of the 
complex was observed for the bound peptide FA9, which was 
well defined inside the peptide-binding groove of HLA-A*0201 
(Figure 2D). The structural properties of the FA9/HLA-A*0201 
complex may be related to the immunogenicity of the epitope that 
allow it to induce specific immune response to against HTNV 
infection.
In vivo induction of Peptide-specific cD8+ 
T cells in hla-a2.1/Kb Tg Mice immunized 
with the hTnV-nP Fa9 Peptide
Having defined the structure of the complex HTNV-NP FA9 
peptide/HLA-A*0201 molecule, we next sought to determine 
the in  vivo immunogenic potential of peptide FA9, which was 
validated for its ability to elicit specific CD8+ T-cell responses 
in vitro in our previous study. Groups of HLA-A2.1/Kb Tg mice 
were immunized or injected with peptide HTNV-NP FA9, pep-
tide HTNV-NP VY9, the HTNV inactivated vaccine, or PBS, as 
described in Section “Materials and Methods.” After three rounds 
of in vivo stimulation, splenocytes from primed mice were first 
tested for IFN-γ production via an ELISPOT assay with peptide 
FA9 as the stimulator. The results showed that a large number of 
CD8+ T cells from Tg mice inoculated with peptide FA9 dem-
onstrated strong IFN-γ production with a median magnitude of 
151 (range, 104–255) SFC/106 splenocytes, which is even higher 
than the IFN-γ secretion level detected in the positive control 
group injected with the HTNV inactivated vaccine (median: 123, 
range: 89–152 SFC/106 splenocytes), although the difference was 
not statistically significant. By contrast, no specific CD8+ T-cell 
reactivity was detected in the splenocytes generated from Tg 
mice injected with PBS (median: 18, range: 14–26 SFC/106 sple-
nocytes) (Figure 3). More importantly, although immunization 
with the FA9 peptide in Tg mice efficiently elicited FA9-specific 
CD8+ T-cell responses, the HLA-B*35-restricted HTNV-NP VY9 
peptide used as an uncorrelated peptide control was unable to 
prime or very inefficiently primed obvious CD8+ T-cell responses 
in the Tg mice, with a median value of 28 (range, 15–55) SFC/106 
splenocytes for IFN-γ production (Figure 3). Notably, compared 
to Tg mice injected with PBS, the SFC count, as an index of the 
CD8+ T-cell reactivity, increased by approximately eightfold 
in the FA9 peptide-immunized mice (p  =  0.021) (Figure  3). 
Moreover, a comparison of IFN-γ secretion between the FA9 
peptide group and the uncorrelated VY9 peptide control group 
revealed a significant quantitative difference in the magnitude of 
peptide FA9-specific CD8+ T-cell responses. Immunization with 
the FA9 peptide elicited significantly stronger IFN-γ producing 
CD8+ T-cell responses than that observed in Tg mice inocula-
tion with the VY9 peptide (p = 0.029) (Figure 3). These results 
indicate that HTNV-NP FA9 peptide can be naturally processed 
in vivo in an HLA-A*02-restricted manner and induce a robust 
FA9-specific CD8+ T-cell response in HLA-A2.1/Kb Tg mice.
hTnV-nP Fa9 Peptide elicited high levels 
of cytokine and cytotoxic Mediator 
Production in hla-a2.1/Kb Tg Mice
To define the phenotype of FA9-responsive CD8+ T cells more 
precisely, splenocytes from each group of HLA-A2.1/Kb Tg mice 
were directly stimulated ex vivo with the FA9 peptide, and the 
number of CD8+ T cells showing specifically inducible cytokine 
secretion and cytotoxic mediator expression was assessed via 
intracellular staining analysis. The representative analyses of these 
distinct patterns of staining are shown in Figure  4A. Overall, 
FigUre 4 | The cytokine and cytolytic mediator production of splenocytes in hla-a2.1/Kb transgenic mice after peptide immunization. The HLA-A2.1/
Kb transgenic mice were divided into four groups (n = 6 each) according to the different immunization, including the HLA-A*02-restricted HTNV-NP FA9 peptide 
(aa129–aa137, FVVPILLKA), the HLA-B*35-restricted HTNV-NP VY9 peptide (aa131–aa139, VPILLKALY), the HTNV vaccine and PBS immunized mice groups, 
respectively. (a) Representative flow cytometric plots of the cytokines interferon (IFN)-γ and tumor necrosis factor (TNF)-α or cytotoxic mediator granzyme 
B-producing and CD107a-expressing CD8+ T cells in splenocytes (vertical) after three immunizations with the HLA-A*02-restricted HTNV-NP FA9 peptide, the 
HLA-B*35-restricted HTNV-NP VY9 peptide, the HTNV vaccine or PBS (horizontal). The numbers indicate the percentage of cells within the boxed regions. (B) 
Comparison of the frequencies (y-axis) of cytokines IFN-γ and TNF-α and cytotoxic mediator granzyme B and the expression percentage of CD107a (x-axis) in the 
peptide FA9-specific CD8+ T cells between the peptide FA9-immunized mice and control mice, including peptide VY9-immunized mice as an unrelated peptide 
control, HTNV-vaccinated mice as a positive control and PBS-administered mice as a negative control, respectively. The results shown are representative of three 
independent experiments. The Wilcoxon rank-sum test was used for statistical evaluation. ns, not significant.
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CD8+ T cells in the splenocytes from Tg mice after immunization 
displayed cytokine or cytotoxic mediator production, predomi-
nantly characterized by IFN-γ, TNF-α, granzyme B secretion, 
and CD107a expression upon stimulation with peptide FA9. 
Consistent with the detection of IFN-γ in the ELISPOT assay, 
a marked high frequency of IFN-γ as the primary cytokine was 
induced in the splenocytes of Tg mice immunized with the FA9 
peptide (median: 8.99%, range: 7.85–11.60% of CD8+ T cells). 
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A high frequency of TNF-α-producing cells was also observed 
in peptide FA9-immunized mice (median: 7.74%, range: 6.34–
11.00% of CD8+ T cells) (Figure 4B). Further analysis revealed 
that the CD8+ T cells displayed adequate cytolytic capacity and 
appeared to be highly functional, secreting cytolytic effector gran-
zyme B (median: 10.45%, range: 8.48–11.30% of CD8+ T cells) 
and upregulating CD107a expression (median: 10.85%, range: 
6.80–15.20% of CD8+ T cells) after stimulation with the FA9 pep-
tide (Figure 4B). Interestingly, similar to what has been observed 
in ex vivo comparisons of IFN-γ production, CD8+ T cells from 
the FA9-immunized mice displayed a trend toward higher levels 
of cytokines production and cytolytic mediator expression than 
the secretion of CD8+ T cells from other control groups. As shown 
in Figure 4B, the Tg mice injected with PBS used as a negative 
control had few or no detectable cells that expressed cytokines 
or cytolytic mediators, and the frequencies of cells expressing 
cytokines or cytolytic mediators were all significantly lower than 
the frequencies induced in the FA9-immunized group (p = 0.001 
for IFN-γ, p = 0.005 for TNF-α, p < 0.001 for granzyme B and 
p = 0.014 for CD107a). The percentages of IFN-γ (median: 7.67%, 
range: 5.88–8.70% of CD8+ T cells), TNF-α (median: 6.09%, 
range: 5.89–6.61% of CD8+ T cells), and granzyme B (median: 
6.81%, range: 5.59–7.26% of CD8+ T cells)-producing CD8+  
T cells in the positive control group inoculated with the HTNV 
inactivated vaccine were slightly lower than the frequencies of 
the FA9 stimulation group, although this difference was not 
significant. However, a higher frequency of CD107a expression 
was observed in the CD8+ T cells from Tg mice immunized with 
peptide FA9 than in those of mice immunized with the HTNV-
inactivated vaccine (median: 4.99%, range: 3.83–5.95% of CD8+ 
T cells, p = 0.041). Importantly, compared with the substantially 
higher frequencies of cytokine secretion and cytolytic mediator 
expression by specific CD8+ T cells in the peptide FA9-immunized 
Tg mice, the Tg mice inoculated with the HLA-B*35-restricted 
VY9 peptide showed much less IFN-γ (median: 2.21%, range: 
1.75–3.11% of CD8+ T cells, p = 0.002), TNF-α (median: 1.40%, 
range: 0.59–3.11% of CD8+ T cells, p = 0.004), and granzyme B 
(median: 2.79%, range: 1.08–3.50% of CD8+ T cells, p < 0.001) 
production and CD107a expression (median: 2.62%, range: 
1.42–2.85% of CD8+ T cells, p = 0.016), further confirming the 
specificity of the HLA–peptide interaction for inducing effective 
T-cell responses. Given that granzyme B release is considered a 
quantitative indicator of the cytotoxic activity of T cells, these 
observations indicated that FA9-specific CTLs with significant 
upregulation of granzyme B and CD107a expression might pos-
sess the cytotoxic capacity to directly kill HTNV-infected cells.
immunization with the hTnV-nP Fa9 
Peptide reduced hTnV Titers in Tissue 
supernatants of hla-a2.1/Kb Tg Mice 
after hTnV challenge
Having demonstrated that HTNV-NP FA9 could elicit high 
levels of specific CD8+ T-cell responses in Tg mice, we then 
conducted HTNV challenge experiments to determine whether 
the peptide FA9-specific CD8+ T-cell responses could defend 
against HTNV infection in vivo and, thus, be used as a vaccine 
candidate. For  this  purpose, we established a model of HTNV 
infection based on replication of the virus in vivo in HLA-A2.1/
Kb Tg mice. The Tg mice were grouped and immunized as before 
and subsequently challenged by the administration of the HTNV 
strain 10 days after immunization. Tissue samples from the cer-
ebrum, heart, liver, spleen, lung, and kidneys of the Tg mice were 
harvested from each mouse on day 4 post-challenge and detected 
for HTNV titer.
The preliminary measurement of the viremia in six organs 
of the HTNV-infected naïve Tg mice showed that high levels of 
HTNV antigens could be detected in the liver, spleen, and kidneys, 
but not in lungs, cerebrum, and heart of the Tg mice, suggesting 
that the liver, spleen, and kidneys are the major organs for infec-
tion and replication of HTNV in HLA-A2.1/Kb Tg mice (Figure 
S3 in Supplementary Material). Consistent with the preliminary 
analyses, few or no detectable virus was found in lungs, cerebrum, 
and heart in all four groups of immunized Tg mice after HTNV 
challenge when HTNV antigens in the tissue supernatant were 
detected via ELISA (Figure 5A).
As expected, after HTNV challenge, each Tg mouse from the 
negative control group injected with PBS displayed evidence of 
high-titer HTNV replication in the tissue supernatant of the liver, 
spleen, and kidneys, whereas a significant reduction of the mean 
viral titer was observed in the organs of the mice immunized 
with the HTNV inactive vaccine (Figure 5B). Importantly, prior 
immunization with peptide FA9 led to a significant decrease in 
HTNV titers in the supernatants of the liver, spleen, and kidneys 
in mean viral titer compared to the negative control Tg mice 
(p = 0.021 for liver, p < 0.001 for spleen, and p = 0.035 for kid-
neys, Figure 5C). However, immunization with irrelevant control 
peptide HTNV-NP VY9 showed still high levels of HTNV titer 
in the supernatants of the liver, spleen, and kidneys in Tg mice, 
which was markedly higher than that in the FA9-immunized 
mice following HTNV challenge (p < 0.001 for liver, p = 0.020 for 
spleen, and p = 0.001 for kidneys, Figure 5C). Notably, although 
FA9 peptide immunization significant decreased the HTNV 
antigen titer in the Tg mice, there was no reduction in the levels 
found in the liver, spleen, and kidneys of the immunized Tg mice 
(Figure 5B), indicating the efficiency of CD8+ T-cell responses 
induced by peptide FA9 to comprehensively inhibit virus replica-
tion and clear the HTNV, therefore protecting against HTNV 
infection in HLA-A2.1/Kb Tg mice.
immunization with the hTnV-nP Fa9 
Peptide inhibited hTnV replication in 
hla-a2.1/Kb Tg Mice to Protect against 
hTnV challenge
The results showing that HTNV-NP FA9 peptide-specific CD8+ 
T-cell responses decreased HTNV titers in tissue supernatants 
of HTNV-infected Tg mice were confirmed following an HTNV 
RNA load analysis for the organs of Tg mice after HTNV challenge. 
As a more sensitive and accurate assay, real-time PCR specific for 
the HTNV S segment was carried out to determine the HTNV 
RNA loads isolated from the organs of the peptide-immunized 
mice challenged with HTNV. As shown in Figure 6A, the HTNV 
RNA in the lungs, cerebrum, and heart was not detectable by 
FigUre 5 | Detection of hTnV antigen with elisa in the organs of hla-a2.1/Kb transgenic mice after hTnV challenge. The HLA-A2.1/Kb transgenic 
mice were divided into four groups (n = 6 each) according to the different immunization, including the mice immunized with the HLA-A*02-restricted HTNV-NP 
peptide FA9 (aa129–aa137, FVVPILLKA), the HLA-B*35-restricted HTNV-NP peptide VY9 (aa131–aa139, VPILLKALY), the HTNV vaccine or PBS, respectively. Ten 
days after the final immunization booster, the mice were challenged with the HTNV 76-118 strain and sacrificed 4 days following HTNV challenge. (a) The HTNV 
antigen (y-axis) was detected in the lungs, liver, cerebrum, spleen, kidneys, and heart (x-axis) of HLA-A2.1/Kb transgenic mice after HTNV infection in the four 
groups, respectively. Few or no detectable virus was found in lungs, cerebrum, and heart in all four groups of immunized transgenic mice after HTNV challenge 
detected via ELISA. (B) Comparison of the HTNV antigen levels (y-axis) in the tissue supernatant of the liver, spleen, and kidneys in each immunized group (x-axis). 
(c) Comparison of the HTNV antigen levels (y-axis) between the HLA-A*02-restricted HTNV-NP peptide FA9immunized mice group and HLA-B*35-restricted 
HTNV-NP peptide VY9-immunized mice group or PBS-injected mice group (x-axis) in the organs liver, spleen and kidneys, respectively. The results shown are 
representative of three independent experiments. A P/N ratio >2.1 is considered positive. The Wilcoxon rank-sum test was used for statistical evaluation. ns, not 
significant.
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real-time PCR. However, we detected significant differences in 
the HTNV RNA loads between the Tg mice that received pep-
tide FA9 inoculation and the mice immunized with the control 
peptide or injected with PBS. In accordance with the results of 
the HTNV antigen detection, significantly lower levels of HTNV 
RNA loads were observed in the liver, spleen, and kidneys of the 
Tg mice after immunization with the FA9 peptide than in those of 
the negative control mice (p < 0.001 for liver, p = 0.007 for spleen, 
and p < 0.001 for kidneys, Figure 6A). The mice immunized with 
the irrelevant control peptide HTNV-NP VY9 showed markedly 
higher levels of HTNV RNA loads in the liver and spleen than 
the FA9-immunized mice (p <  0.001 for liver and p =  0.010 
for spleen, Figure  6A), whereas no significant difference was 
observed for HTNV RNA loads in the kidneys between the VY9 
peptide-treated mice and the FA9-immunized mice (Figure 6A), 
although the inhibitory tendency of the HTNV RNA loads in 
the FA9 peptide immunization group was still observed in the 
kidneys. Notably, when the capacity of FA9 peptide immuniza-
tion to reduce the HTNV RNA loads was compared among dif-
ferent organs of the Tg mice, the HTNV RNA loads in liver were 
lower than those in the spleen (p = 0.029) or kidneys (p = 0.018) 
(Figure 6B), indicating that there may be tissue specificity of the 
peptide FA9-induced CD8+ T-cell responses for inhibiting HTNV 
replication. Together, these data clearly suggest that the inhibition 
of HTNV replication in the liver, spleen, and kidneys of Tg mice 
can be mediated by FA9-specific CD8+ T-cell responses, which 
FigUre 6 | Detection of hTnV rna loads via real-time Pcr in the organs of hTnV-challenged hla-a2.1/Kb transgenic mice. The HLA-A2.1/Kb 
transgenic mice were divided into four groups (n = 6 each), including the mice immunized with HLA-A*02-restricted HTNV-NP peptide FA9 (aa129–aa137, 
FVVPILLKA), HLA-B*35-restricted HTNV-NP peptide VY9 (aa131–aa139, VPILLKALY), HTNV vaccine or PBS, respectively. Ten days after the final immunization 
booster, the mice were challenged with the HTNV 76-118 strain and sacrificed 4 days following HTNV challenge. (a) The detection of HTNV RNA loads (y-axis) in 
the lungs, liver, cerebrum, spleen, kidneys, and heart (x-axis) of HLA-A2.1/Kb transgenic mice after HTNV challenge in the four groups. Comparison of the HTNV 
RNA loads that could be detected in liver, spleen, and kidneys of the immunized transgenic mice after HTNV challenge among four immunization mice groups. 
(B) The HTNV RNA loads (y-axis) in the liver, spleen, and kidneys of each immunized group (x-axis) and comparison of the HTNV RNA loads between the liver 
and spleen or between the liver and kidneys in the HLA-A*02-restricted HTNV-NP peptide FA9-immunized mice group. The results shown were recorded as 
cycle time (Ct) and quantified by 2−ΔΔCt and were representative of three independent experiments. The Wilcoxon rank-sum test was used for statistical 
evaluation. ns, not significant.
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may play an essential role in the partial in vivo HTNV clearance 
in HLA-A2.1/Kb Tg mice.
DiscUssiOn
For prevention of infectious diseases, the use of therapeutic or 
prophylactic vaccines can be a successful method for directing 
the immune system against specific pathogens. A peptide vaccine 
with greater efficacy against pathogens would bring about a major 
improvement in protection of the population against infection 
(38–40). Our previous findings that the T-cell response was an 
important component of naturally acquired immunity to control 
HTNV infection provide the foundation for the development of 
HTNV peptide vaccines that may combat HTNV by efficiently 
inducing specific T-cell immunities. In this study, we reported 
that the HTNV-NP FA9 peptide could be an immunogenic 
epitope, which was determined based on its binding with HLA-
A*0201 molecules and its in  vivo functional validation. We 
further provided evidence that immunization with peptide FA9 
in HLA-A2.1/Kb Tg mice successfully generated reactive CD8+ 
T cell responses that inhibited HTNV infection after HTNV chal-
lenge, suggesting that peptide FA9 may be a good candidate for 
use in the design of HTNV peptide vaccines.
Inactivated vaccines for HTNV in Asia have been proved 
to boost the humoral responses; however, the titers of HTNV-
specific neutralizing antibodies are not sufficiently high in 
some populations and, therefore, are not expected to be able to 
effectually limit HTNV amplification and completely prevent 
infection (13, 14, 41, 42). As such, there is a concerted drive to 
develop peptide vaccines that can efficaciously induce HTNV-
directed T-cell immunity. Previous evidence has illustrated the 
feasibility, safety, and immunogenicity of the peptide vaccine 
(43, 44). However, due to MHC restrictions and low immuno-
genicity, the broad applicability of peptide vaccines for diseases 
may be currently limited. Several studies on various clinical 
applications of peptide vaccines have suggested that many 
potential variables, such as the type and length of peptides, 
the loading of one or multiple peptides on antigen-presenting 
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cells (APCs) or the route of administration may attribute to 
the design efficiency of peptide vaccines (25, 39, 40). Selecting 
the right epitope is the first crucial step in the design of an 
effective vaccine.
A number of methods have been proposed for the identifica-
tion of T-cell epitopes based on the binding ability of the predic-
tor peptide to MHC molecules (45, 46). As reported previously, 
multiple HLA class I-restricted CTL epitopes of HTNV-NP have 
been identified using overlapping peptides map screen methods 
in HFRS patients, one of which was the peptide FA9 restricted by 
HLA-A*02 (21). Our findings also showed that the HTNV-NP 
FA9 epitope could prime specific CD8+ T-cell responses in 
HLA-A*02 HFRS patients. Intriguingly, patients with higher 
levels of CD8+ T-cell responses to the FA9 epitope maintained 
mild or moderate HFRS severity (21). Notably, HLA-A*02 allele-
restricted epitopes are suggested for further studies because of 
their potential immunogenicity in Chinese Han populations 
where HLA-A*02 alleles predominate as high as 29.70% (27, 28). 
Hence, in this study, we selected the HTNV-NP FA9 peptide for 
further evaluation of its potential immunogenicity to be used as 
a candidate for peptide vaccine designs.
We, thus, investigated the structural features of the FA9/
HLA-A*0201complex. The electron densities of the FA9 pep-
tide that bound to HLA-A*0201 were unambiguous. The high 
quality of the overall structure of the pHLA complex allowed 
for a detailed discussion of the FA9–HLA-A*0201 binding 
characteristics. The crystal structure analysis offered the oppor-
tunity to determine whether the binding sites between FA9 and 
HLA-A*0201 interact with one another, thereafter evaluating 
the binding affinity of the peptide FA9 to HLA-A*0201 mol-
ecules. In general, the peptides among MHC class I molecules 
are usually considered to be 8–10 aas long and contain anchor 
residues for the preferred MHC allele. The exact localization of 
the anchor residues of the peptide relies on each specific MHC 
allele. Whether these anchor residues can stably interact with 
MHC allele-specific pockets is a key determinant in evaluating 
the affinity of a peptide–MHC (pMHC) molecule (47, 48). In 
particular, the residue in position 2 from the N termini and the 
residue on the C termini are the known primary anchor positions 
for binding of the 9-mer peptides to HLA-A*02 molecules, and 
the residues at positions 3 and 6 are common secondary anchors 
in some peptide/HLA-A*02 complexes (49–51). To provide a 
more accurate analysis of the pHLA, a template GV9 peptide 
taken directly from the co-crystallized X-ray structure (PDB 
code 3I6G) was used in our homology structure modeling for 
the viral pHLA complexes. Our results revealed that the general 
conformation and position of FA9 within the peptide-binding 
groove of HLA-A*0201were similar to the structure observed in 
GV9/HLA-A*0201, and peptide FA9 contains an optimal HLA-
A*02-binding motif, that is, Val at the P2 anchor position and 
Ala at the C-terminal P9 anchor position. However, peptide FA9 
bound with HLA-A*0201 molecules via residue Val in position 
3 and Leu in position 7 as secondary anchor residues, which 
appeared to be the eminent feature of peptide FA9. Despite these 
observed structural differences between the two peptides at the 
binding sites, the side chain of the P3 residue, occupying identi-
cal positions in both the FA9 and GV9 complex, act as the same 
secondary anchor residues. Thus, peptide FA9 fits well into the 
binding groove formed at the interface of the pHLA. The stable 
interaction of peptide FA9 anchor residues with HLA-A*0201 
molecules could improve the binding affinity of the complex, 
which may affect the immunodominance of peptide-specific 
CTL responses.
It has been reported previously that the biophysical and 
structural landscape of the pMHC complex plays a critical role 
in TCR selection (52–54), and the flexibility of the peptide in 
the MHC groove might affect the responding TCR repertoire 
(55). Here, we reported that in the middle portion of peptide 
FA9, the residues Phe1, Pro4, Ile5, Leu6, and Lys8 extruding out 
of the MHC binding groove may predominantly contribute in 
interactions with TCR, indicating that the FA9/HLA-A*0201 
complex may have ordinary properties as a cell-surface ligand 
for recognition by T cells. Multiple mechanisms have been 
proposed for TCR and pMHC recognition and binding (56–58). 
Because the peptide needs to be presented on the viral-infected 
cells by MHC molecules at sufficient expression levels to further 
form stable synapses between the antigen-presenting cells and 
the effector T cells (59), high TCR to pMHC affinity appears to 
be a decisive factor for the T-cell immunogenic potential and 
necessary for specific T cells to completely clear the viruses. In 
published studies, the kinetic release rate of TCRs from pMHC 
complexes was found to be most often correlated with T-cell 
activation (60, 61). The FA9/HLA-A*0201 complex structure 
determined here implied that the major contacts between TCRs 
and peptides might be the central hydrophobic residues of 
the viral peptide. Thus, we speculated that the strong antiviral 
efficacy of the CTL response induced by FA9 might be primarily 
derived from the favorable hydrophobic interplay between the 
central peptide residues and the corresponding hydrophobic 
residues in the complementary-determining region (CDR) 
loops of TCRs. However, given that TCR–peptide recognition 
is mainly determined by the highly flexible and variable CDR 
loops of TCRs, the TCR–pMHC complex cannot be easily 
extrapolated (24). Therefore, the definite structure and the 
affinity for peptide FA9-specific αβTCRs to interact with pHLA 
complexes have not been fully elucidated, which requires further 
studies in the future.
It is also noteworthy that functional validation should be 
performed to ultimately determine immunogenic T-cell epitopes. 
These structural analyses were then further validated by examin-
ing the immunogenicity and antiviral efficacy of peptide FA9 in 
HLA-A2.1/Kb Tg mice. It is important to note that peptides that 
elicit effective CTL responses must first successfully to be pre-
sented by MHC class I molecules. The peptides administered to 
the mice mimicked the epitopes present on the target cells when 
associated with the restricting MHC molecule and are, thus, 
capable of inducing relevant immune responses (25). In the pre-
sent study, vaccination with the HLA-A*02-restricted HTNV-NP 
FA9 peptide induced FA9-specific CD8+ T-cell responses in HLA-
A2.1/Kb Tg mice, whereas HLA-B*35-restricted HTNV-NP VY9 
peptide vaccination generated relatively poor overall reactivity. 
In an HTNV challenge trial, there was a significant reduction 
in both the HTNV antigen level and RNA loads of HTNV in 
the HLA-A2.1/Kb Tg mice vaccinated with the HTNV-NP FA9 
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peptide compared to unvaccinated Tg mice and compared to 
the HLA-B*35-restricted VY9 peptide-vaccinated group. These 
findings indicated that the responses could be inferred as due to 
the presence of FA9-specific CTLs, which could be proposed to 
be evidence for natural recognition of the FA9 peptide in vivo. 
Moreover, by examining and comparing the responses to the 
HLA-A*02-restricted FA9 and HLA-B*35-restricted VY9 peptide 
in Tg mice, we identified that peptide FA9 could be processed 
and presented through the classical HLA-A*02-restricted man-
ner, which further primed and boosted specific CTL responses to 
control HTNV infection in vivo. These results are important for 
the selection of antigenic targets that can be applied in vaccine 
design to induce protective CD8+ T-cell responses. In addition, 
compared to the external glycoproteins of HTNV, the conserva-
tion of the HTNV-NP antigen among different subtypes derived 
from hantaviruses is generally high (21). Thus, HTNV-NP FA9 
epitope that was highly immunogenic in humans might also be 
a potent immunogen capable of inducing CD8+ T-cell responses 
against HTNV infection in Tg mice, combined with its high 
conservation, making it an ideal candidate for the development 
of novel peptide vaccines.
Although antigen-specific IFN-γ production is often used 
as a biomarker for virus infection, it is possible that additional 
cytokines might allow more specific or qualitatively different 
detection of immune responses against virus infection. To further 
characterize the cellular immune responses specific to HTNV-NP 
FA9 peptides, additional cytokines and cytotoxic mediators were 
tested in the splenocytes of immunized Tg mice after ex vivo 
stimulation with the FA9 peptide. In consistent with the data 
obtained in the ELISPOT assay, immunization with FA9 induced 
a high percentage of IFN-γ production in the CD8+ T cells. 
TNF-α is a proinflammatory cytokine produced by many types 
of immunocytes that can enhance Th1 responses, promote CTL 
activation, and drive antiviral immunity (62). In mice immunized 
with peptide FA9, an increase in TNF-α expression was observed, 
as expected. The secretion of granzyme B and the expression of 
CD107a, which is primarily induced by activated CTLs (63), were 
also observed to a higher extent in FA9-immunized Tg mice, sug-
gesting that HTNV-NP FA9 peptide-specific CD8+ T cells owned 
a strong cytolytic capacity against HTNV infection. The rapid 
production of IFN-γ or granules by T cells is important in the 
defense against HTNV infections. Similar results were observed 
in Tg mice using HTNV-inactivated vaccine immunization, in 
which case the percentages of cytokine- or cytotoxic mediator-
producing CD8+ T cells were significantly higher, whereas 
peptide VY9-immunized Tg mice had few or no detectable cells 
expressing cytokines, indicating that the 9-mer peptide presenta-
tion requires the matched context of HLA class I molecule.
Notably, the HLA-A2.1/Kb Tg mouse model that has been 
shown to be suitable for the identification of human HLA-
A*0201-restricted T-cell epitopes was used in this study (64, 
65). In the HTNV challenge experiments, peptide FA9 was as 
protective as HTNV inactive vaccines, and a similar level of 
CD8+ T-cell responses were observed following both vaccina-
tion regimens, suggesting that peptide FA9-primed immune 
protection is achievable in this mice model. However, there 
may be some disadvantages of this Tg mouse model for HTNV 
challenge, as mice are considered a natural reservoir for HTNV 
but do not develop the disease or symptoms (66). Therefore, 
we could not evaluate the antivirus effect of the peptide FA9-
induced CTL response via a reduction or elimination of disease 
symptoms. The parameters selected to assess protection were 
measurements of viral loads in the major organs of the Tg mice. 
Quantification of HTNV S gene expression encoding the NP 
with real-time RT-PCR and detection of the HTNV antigen via 
ELISA in the organs of the mice following HTNV challenge have 
been shown to be good methods for evaluating HTNV viral 
loads in mice (67). Based on the peak of virus replication, we 
chose 3 days post-challenge for detection. Our results indicated 
that immunization of the HLA-A2.1/Kb Tg mice with peptide 
FA9 followed by HTNV challenge inhibited HTNV replication 
and enhanced the clearance of HTNV from the liver, spleen, 
and kidneys of the mice. In the same Tg mice group immunized 
with peptide FA9, further comparisons showed that the HTNV 
RNA load in the liver was slightly lower than that in the spleen 
and kidneys, which was in accordance with the results found in 
the Tg mice injected with PBS, indicating that even without pre-
immunization, the HTNV infection may vary among tissues in 
Tg mice. In fact, different expressions of tissue-selective homing 
lymphocyte receptors at the site of antigen exposure and dif-
ferent tissue-specific APCs may lead to different outcomes in 
the induction of T cells and the impact on sequential antigen-
specific responses (68, 69).
In summary, the structural features of the HTNV-NP FA9 
peptide/HLA-A*02 molecule complex were analyzed in this 
study. As far as we know, this is the first report of the crystal 
structure of the HTNV-NP CTL epitope upon interaction 
with HLA molecules, through which we confirmed that the 
HTNV-NP FA9 peptide was a highly immunogenic epitope 
restricted by HLA-A*02. By challenging HLA-A2.1/Kb Tg mice 
with HTNV in  vivo, we revealed the in  vivo immunogenicity 
of the HTNV-NP peptide FA9 and the antiviral efficiency of 
FA9-specific CTL responses. The important findings presented 
here indicated that the HTNV-NP FA9 peptide has high efficacy 
and immunogenicity for inducing protective immunity and can 
be used in regimens for further peptide vaccine designs. These 
observations provide further structural and functional insights 
regarding T-cell-mediated antiviral immunity in HTNV infec-
tion, which may have important implications for both HFRS 
immunotherapy and HTNV peptide vaccine development. 
However, the relationship between the TCR-FA9/HLA-A*02 
binding and the function of FA9 peptide-specific CTLs is 
unknown. In follow-up studies, the binding affinity of FA9/
HLA-A*02 to specific TCRs should be measured to determine 
how TCRs interact with their cognate pHLAs to active T cells 
and induce CTL responses.
aUThOr cOnTriBUTiOns
The study was conceived and experiments designed by BJ, YM, 
and FZ. The experiments were performed by YM, LFC, and BY. 
Data were analyzed and interpreted by YM, LFC, BJ, and FZ. 
YusiZ, CZ, YunZ, KT, and RZ contributed to the reagents, materi-
als, or analysis tools. While YM and BY drafted the paper, LC, 
14
Ma et al. T-Cell Immunity against Hantaan Virus
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 298
KY, BJ, and FZ all critically revised the manuscript for important 
intellectual content.
acKnOWleDgMenTs
The authors would like to thank the research group of Dr. George 
Fu Gao at CAS Key Laboratory of Pathogenic Microbiology and 
Immunology, Institute of Microbiology, Chinese Academy of 
Sciences, Beijing, China for their helpful assistance in the crystal 
structure analysis in this study. We are grateful to the anonymous 
reviewers for their helpful comments, valuable suggestions, and 
critical review of the manuscript.
FUnDing
This study was supported by grants from the National Natural 
Science Foundation of China (No. 81401297), the National Basic 
Research Program of China (No. 2012CB518905), and Natural 
Science Foundation Research Project of Shaanxi province in 
China (No. 2015JQ8295).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00298
reFerences
1. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Makela S, et al. 
Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol (2013) 
11(8):539–50. doi:10.1038/nrmicro3066 
2. Watson DC, Sargianou M, Papa A, Chra P, Starakis I, Panos G. Epidemiology 
of Hantavirus infections in humans: a comprehensive, global overview. Crit 
Rev Microbiol (2014) 40(3):261–72. doi:10.3109/1040841X.2013.783555 
3. Krautkramer E, Zeier M, Plyusnin A. Hantavirus infection: an emerging 
infectious disease causing acute renal failure. Kidney Int (2013) 83(1):23–7. 
doi:10.1038/ki.2012.360 
4. Vaheri A, Henttonen H, Voutilainen L, Mustonen J, Sironen T, Vapalahti O. 
Hantavirus infections in Europe and their impact on public health. Rev Med 
Virol (2013) 23(1):35–49. doi:10.1002/rmv.1722 
5. Macneil A, Nichol ST, Spiropoulou CF. Hantavirus pulmonary syndrome. 
Virus Res (2011) 162(1–2):138–47. doi:10.1016/j.virusres.2011.09.017 
6. Jiang H, Du H, Wang LM, Wang PZ, Bai XF. Hemorrhagic fever with renal 
syndrome: pathogenesis and clinical picture. Front Cell Infect Microbiol (2016) 
6:1. doi:10.3389/fcimb.2016.00001 
7. Zhang WY, Wang LY, Liu YX, Yin WW, Hu WB, Magalhaes RJ, et  al. 
Spatiotemporal transmission dynamics of hemorrhagic fever with renal 
syndrome in China, 2005–2012. PLoS Negl Trop Dis (2014) 8(11):e3344. 
doi:10.1371/journal.pntd.0003344 
8. Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans 
and animals, China. Emerg Infect Dis (2010) 16(8):1195–203. doi:10.3201/
eid1608.090470 
9. Yan L, Fang LQ, Huang HG, Zhang LQ, Feng D, Zhao WJ, et al. Landscape 
elements and Hantaan virus-related hemorrhagic fever with renal syndrome, 
People’s Republic of China. Emerg Infect Dis (2007) 13(9):1301–6. doi:10.3201/
eid1309.061481 
10. Ge XY, Yang WH, Pan H, Zhou JH, Han X, Zhu GJ, et al. Fugong virus, a novel 
hantavirus harbored by the small oriental vole (Eothenomys eleusis) in China. 
Virol J (2016) 13(1):27. doi:10.1186/s12985-016-0532-4 
11. Gu SH, Hejduk J, Markowski J, Markowski M, Liberski PP, Yanagihara R. Whole-
genome sequence of a novel hantavirus isolated from the European mole (Talpa 
europaea). Genome Announc (2015) 3(3):e00508–15. doi:10.1128/genomeA. 
00508-15 
12. Xu L, Wu J, He B, Qin S, Xia L, Qin M, et  al. Novel hantavirus identified 
in black-bearded tomb bats, China. Infect Genet Evol (2015) 31:158–60. 
doi:10.1016/j.meegid.2015.01.018 
13. Song JY, Woo HJ, Cheong HJ, Noh JY, Baek LJ, Kim WJ. Long-term immuno-
genicity and safety of inactivated Hantaan virus vaccine (Hantavax) in healthy 
adults. Vaccine (2016) 34(10):1289–95. doi:10.1016/j.vaccine.2016.01.031 
14. Liu X, Zhang T, Xie C, Xie Y. Changes of HFRS incidence caused by vac-
cine intervention in Yichun City, China, 2005–2013. Med Sci Monit (2016) 
22:295–301. doi:10.12659/MSM.895886
15. Zeier M, Handermann M, Bahr U, Rensch B, Muller S, Kehm R, et al. New 
ecological aspects of hantavirus infection: a change of a paradigm and a chal-
lenge of prevention – a review. Virus Genes (2005) 30(2):157–80. doi:10.1007/
s11262-004-5625-2 
16. Yan G, Zhang Y, Ma Y, Yi J, Liu B, Xu Z, et al. Identification of a novel B-cell 
epitope of Hantaan virus glycoprotein recognized by neutralizing 3D8 
monoclonal antibody. J Gen Virol (2012) 93(Pt 12):2595–600. doi:10.1099/
vir.0.045302-0 
17. Van Epps HL, Terajima M, Mustonen J, Arstila TP, Corey EA, Vaheri A, et al. 
Long-lived memory T lymphocyte responses after hantavirus infection. J Exp 
Med (2002) 196(5):579–88. doi:10.1084/jem.20011255 
18. Manigold T, Mori A, Graumann R, Llop E, Simon V, Ferres M, et al. Highly 
differentiated, resting gn-specific memory CD8+ T cells persist years after 
infection by andes hantavirus. PLoS Pathog (2010) 6(2):e1000779. doi:10.1371/
journal.ppat.1000779 
19. Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of 
specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic 
fever, hantavirus pulmonary syndrome. J Immunol (2004) 172(5):3297–304. 
doi:10.4049/jimmunol.172.5.3297 
20. Ma Y, Yuan B, Zhuang R, Zhang Y, Liu B, Zhang C, et  al. Hantaan virus 
infection induces both Th1 and ThGranzyme B+ cell immune responses that 
associated with viral control and clinical outcome in humans. PLoS Pathog 
(2015) 11(4):e1004788. doi:10.1371/journal.ppat.1004788 
21. Ma Y, Wang J, Yuan B, Wang M, Zhang Y, Xu Z, et al. HLA-A2 and B35 restricted 
hantaan virus nucleoprotein CD8+ T-cell epitope-specific immune response 
correlates with milder disease in hemorrhagic fever with renal syndrome. 
PLoS Negl Trop Dis (2013) 7(2):e2076. doi:10.1371/journal.pntd.0002076 
22. Wang M, Wang J, Zhu Y, Xu Z, Yang K, Yang A, et al. Cellular immune response 
to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever 
with renal syndrome: correlation with disease severity. J Infect Dis (2009) 
199(2):188–95. doi:10.1086/595834 
23. Smith C, Gras S, Brennan RM, Bird NL, Valkenburg SA, Twist KA, et  al. 
Molecular imprint of exposure to naturally occurring genetic variants of 
human cytomegalovirus on the T cell repertoire. Sci Rep (2014) 4:3993. 
doi:10.1038/srep03993 
24. Xia Z, Chen H, Kang SG, Huynh T, Fang JW, Lamothe PA, et al. The complex 
and specific pMHC interactions with diverse HIV-1 TCR clonotypes reveal 
a structural basis for alterations in CTL function. Sci Rep (2014) 4:4087. 
doi:10.1038/srep04087 
25. Hoppes R, Oostvogels R, Luimstra JJ, Wals K, Toebes M, Bies L, et al. Altered 
peptide ligands revisited: vaccine design through chemically modified HLA-
A2-restricted T cell epitopes. J Immunol (2014) 193(10):4803–13. doi:10.4049/
jimmunol.1400800 
26. Wu Y, Gao F, Liu J, Qi J, Gostick E, Price DA, et al. Structural basis of diverse 
peptide accommodation by the rhesus macaque MHC class I molecule 
Mamu-B*17: insights into immune protection from simian immunodeficiency 
virus. J Immunol (2011) 187(12):6382–92. doi:10.4049/jimmunol.1101726 
27. Shen CM, Zhu BF, Ye SH, Liu ML, Yang G, Liu S, et  al. Allelic diversity 
and haplotype structure of HLA loci in the Chinese Han population living 
in the Guanzhong region of the Shaanxi province. Hum Immunol (2010) 
71(6):627–33. doi:10.1016/j.humimm.2010.02.012 
28. Shen C, Zhu B, Liu M, Li S. Genetic polymorphisms at HLA-A, -B, and -DRB1 
loci in Han population of Xi’an city in China. Croat Med J (2008) 49(4):476–82. 
doi:10.3325/cmj.2008.4.476 
29. Di Mario G, Garulli B, Sciaraffia E, Facchini M, Donatelli I, Castrucci MR. 
A heat-inactivated H7N3 vaccine induces cross-reactive cellular immu-
nity in HLA-A2.1 transgenic mice. Virol J (2016) 13(1):56. doi:10.1186/
s12985-016-0513-7 
15
Ma et al. T-Cell Immunity against Hantaan Virus
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 298
30. Thomas S, Klobuch S, Podlech J, Plachter B, Hoffmann P, Renzaho A, et al. 
Evaluating human T-cell therapy of cytomegalovirus organ disease in HLA-
transgenic mice. PLoS Pathog (2015) 11(7):e1005049. doi:10.1371/journal.
ppat.1005049 
31. Huang YH, Terabe M, Pendleton CD, Stewart Khursigara D, Bera TK, 
Pastan I, et al. Identification and enhancement of HLA-A2.1-restricted CTL 
epitopes in a new human cancer antigen-POTE. PLoS One (2013) 8(6):e64365. 
doi:10.1371/journal.pone.0064365 
32. Ma C, Wang Z, Li S, Xing Y, Wu R, Wei J, et al. Analysis of an outbreak of 
hemorrhagic fever with renal syndrome in college students in Xi’an, China. 
Viruses (2014) 6(2):507–15. doi:10.3390/v6020507 
33. Liu J, Sun Y, Qi J, Chu F, Wu H, Gao F, et al. The membrane protein of severe 
acute respiratory syndrome coronavirus acts as a dominant immunogen 
revealed by a clustering region of novel functionally and structurally defined 
cytotoxic T-lymphocyte epitopes. J Infect Dis (2010) 202(8):1171–80. 
doi:10.1086/656315 
34. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding 
and crystallization of molecules expressed in Escherichia coli and complexed 
with single antigenic peptides. Proc Natl Acad Sci U S A (1992) 89(8):3429–33. 
doi:10.1073/pnas.89.8.3429 
35. Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, et  al. Identification and 
structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 
derived from the H5N1 subtype of influenza A viruses. J Gen Virol (2010) 
91(Pt 4):919–30. doi:10.1099/vir.0.016766-0 
36. Zhang J, Jia Z, Lin Z, Li J, Fu X, Huang Y, et al. Computational prediction and 
experimental assessment of an HLA-A*0201-restricted cytotoxic T lympho-
cyte epitope from neutral endopeptidase. Immunol Res (2012) 52(3):231–9. 
doi:10.1007/s12026-012-8330-6 
37. Cheng L, Yu L, Wu X, Li K, Wang F, Zhang L, et  al. Induction of specific 
humoral and cellular immune responses in a mouse model following gene 
fusion of HSP70C and Hantaan virus Gn and S0.7 in an adenoviral vector. 
PLoS One (2014) 9(2):e88183. doi:10.1371/journal.pone.0088183 
38. Takano T, Tomizawa K, Morioka H, Doki T, Hohdatsu T. Evaluation of 
protective efficacy of the synthetic peptide vaccine containing the T-helper 
1 epitope with CpG oligodeoxynucleotide against feline infectious perito-
nitis virus infection in cats. Antivir Ther (2014) 19(7):645–50. doi:10.3851/ 
IMP2735 
39. Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell 
responses to viral infections  –  opportunities for Peptide vaccination. Front 
Immunol (2014) 5:171. doi:10.3389/fimmu.2014.00171 
40. Griffiths KL, Khader SA. Novel vaccine approaches for protection against 
intracellular pathogens. Curr Opin Immunol (2014) 28:58–63. doi:10.1016/j.
coi.2014.02.003 
41. Wang JJ, Wei ZZ, Wei J, Ma CA, Dong JH, Lu XL, et al. [Long term epidemiolog-
ical effects of vaccination on hemorrhagical fever with renal syndrome (HFRS) 
in Shaanxi provincial HFRS epidemic areas]. Zhonghua Liu Xing Bing Xue Za 
Zhi (2012) 33(3):309–12. doi:10.3760/cma.j.issn.0254-6450.2012.03.014
42. Chen Y, Yang X, Ye F, Chen T, Liu Z, Zhao Y. History of incomplete vaccination 
may associate with occurrence of hemorrhagic fever with renal syndrome with 
relieved clinical symptoms. J Med Virol (2016) 88(7):1168–72. doi:10.1002/
jmv.24443 
43. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. 
Improved survival with ipilimumab in patients with metastatic melanoma. N 
Engl J Med (2010) 363(8):711–23. doi:10.1056/NEJMoa1003466 
44. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving 
beyond current vaccines. Nat Med (2004) 10(9):909–15. doi:10.1038/ 
nm1100 
45. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, Lund O, et  al. 
An integrative approach to CTL epitope prediction: a combined algorithm 
integrating MHC class I binding, TAP transport efficiency, and proteasomal 
cleavage predictions. Eur J Immunol (2005) 35(8):2295–303. doi:10.1002/
eji.200425811 
46. Saethang T, Hirose O, Kimkong I, Tran VA, Dang XT, Nguyen LA, et  al. 
EpicCapo: epitope prediction using combined information of amino acid 
pairwise contact potentials and HLA-peptide contact site information. BMC 
Bioinformatics (2012) 13:313. doi:10.1186/1471-2105-13-313 
47. Rudolph MG, Wilson IA. The specificity of TCR/pMHC interaction. Curr 
Opin Immunol (2002) 14(1):52–65. doi:10.1016/S0952-7915(01)00298-9 
48. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, et al. Ligand rec-
ognition by alpha beta T cell receptors. Annu Rev Immunol (1998) 16:523–44. 
doi:10.1146/annurev.immunol.16.1.523 
49. Williams A, Peh CA, Elliott T. The cell biology of MHC class I antigen pre-
sentation. Tissue Antigens (2002) 59(1):3–17. doi:10.1034/j.1399-0039.2002. 
590103.x 
50. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by 
MHC class I molecules. Annu Rev Immunol (1993) 11:213–44. doi:10.1146/ 
annurev.iy.11.040193.001241 
51. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for 
the recognition of peptide antigens by MHC class I molecules. Science (1992) 
257(5072):927–34. doi:10.1126/science.1323878 
52. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants 
of T-cell receptor bias in immunity. Nat Rev Immunol (2006) 6(12):883–94. 
doi:10.1038/nri1977 
53. Theodossis A, Guillonneau C, Welland A, Ely LK, Clements CS, Williamson 
NA, et  al. Constraints within major histocompatibility complex class I 
restricted peptides: presentation and consequences for T-cell recognition. Proc 
Natl Acad Sci U S A (2010) 107(12):5534–9. doi:10.1073/pnas.1000032107 
54. Burrows SR, Chen Z, Archbold JK, Tynan FE, Beddoe T, Kjer-Nielsen L, et al. 
Hard wiring of T cell receptor specificity for the major histocompatibility 
complex is underpinned by TCR adaptability. Proc Natl Acad Sci U S A (2010) 
107(23):10608–13. doi:10.1073/pnas.1004926107 
55. Miles JJ, Borg NA, Brennan RM, Tynan FE, Kjer-Nielsen L, Silins SL, et al. TCR 
alpha genes direct MHC restriction in the potent human T cell response to a 
class I-bound viral epitope. J Immunol (2006) 177(10):6804–14. doi:10.4049/
jimmunol.177.10.6804 
56. Borbulevych OY, Piepenbrink KH, Gloor BE, Scott DR, Sommese RF, 
Cole DK, et al. T cell receptor cross-reactivity directed by antigen-dependent 
tuning of peptide-MHC molecular flexibility. Immunity (2009) 31(6):885–96. 
doi:10.1016/j.immuni.2009.11.003 
57. Yin Y, Mariuzza RA. The multiple mechanisms of T cell receptor cross-reactiv-
ity. Immunity (2009) 31(6):849–51. doi:10.1016/j.immuni.2009.12.002 
58. Macdonald WA, Chen Z, Gras S, Archbold JK, Tynan FE, Clements CS, et al. 
T cell allorecognition via molecular mimicry. Immunity (2009) 31(6):897–908. 
doi:10.1016/j.immuni.2009.09.025 
59. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, et al. Relapse or 
eradication of cancer is predicted by peptide-major histocompatibility com-
plex affinity. Cancer Cell (2013) 23(4):516–26. doi:10.1016/j.ccr.2013.03.018 
60. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, et  al. 
Enhanced antigen-specific antitumor immunity with altered peptide ligands 
that stabilize the MHC-peptide-TCR complex. Immunity (2000) 13(4):529–38. 
doi:10.1016/S1074-7613(00)00052-2 
61. Bowerman NA, Colf LA, Garcia KC, Kranz DM. Different strategies adopted 
by K(b) and L(d) to generate T cell specificity directed against their respective 
bound peptides. J Biol Chem (2009) 284(47):32551–61. doi:10.1074/jbc.
M109.040501 
62. Wohlleber D, Kashkar H, Gartner K, Frings MK, Odenthal M, Hegenbarth S, 
et al. TNF-induced target cell killing by CTL activated through cross-presen-
tation. Cell Rep (2012) 2(3):478–87. doi:10.1016/j.celrep.2012.08.001 
63. Popescu I, Pipeling M, Akulian J, McDyer J. Phenotypic and functional 
characterization of cytotoxic T lymphocytes by flow cytometry. Methods Mol 
Biol (2014) 1186:21–47. doi:10.1007/978-1-4939-1158-5_3 
64. Dervillez X, Qureshi H, Chentoufi AA, Khan AA, Kritzer E, Yu DC, et  al. 
Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex 
virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from 
seropositive asymptomatic individuals and protect HLA transgenic mice 
against ocular herpes. J Immunol (2013) 191(10):5124–38. doi:10.4049/
jimmunol.1301415 
65. Srivastava R, Khan AA, Spencer D, Vahed H, Lopes PP, Thai NT, et al. HLA-
A02:01-restricted epitopes identified from the herpes simplex virus tegument 
protein VP11/12 preferentially recall polyfunctional effector memory CD8+ 
T cells from seropositive asymptomatic individuals and protect humanized 
HLA-A*02:01 transgenic mice against ocular herpes. J Immunol (2015) 
194(5):2232–48. doi:10.4049/jimmunol.1402606 
66. Yu XJ, Tesh RB. The role of mites in the transmission and maintenance of 
Hantaan virus (Hantavirus: Bunyaviridae). J Infect Dis (2014) 210(11):1693–9. 
doi:10.1093/infdis/jiu336 
16
Ma et al. T-Cell Immunity against Hantaan Virus
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 298
67. Jiang DB, Sun YJ, Cheng LF, Zhang GF, Dong C, Jin BQ, et al. Construction 
and evaluation of DNA vaccine encoding Hantavirus glycoprotein N-terminal 
fused with lysosome-associated membrane protein. Vaccine (2015) 
33(29):3367–76. doi:10.1016/j.vaccine.2015.05.007 
68. Takamura S, Roberts AD, Jelley-Gibbs DM, Wittmer ST, Kohlmeier JE, 
Woodland DL. The route of priming influences the ability of respiratory 
virus-specific memory CD8+ T cells to be activated by residual antigen. J Exp 
Med (2010) 207(6):1153–60. doi:10.1084/jem.20090283 
69. Belkaid Y, Oldenhove G. Tuning microenvironments: induction of regulatory 
T cells by dendritic cells. Immunity (2008) 29(3):362–71. doi:10.1016/j.
immuni.2008.08.005 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Ma, Cheng, Yuan, Zhang, Zhang, Zhang, Tang, Zhuang, Chen, 
Yang, Zhang and Jin. This is an open-access article distributed under the terms of 
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
